The Prognostic application of LFA‑based cardiac markers focuses on longitudinal risk assessment and outcome prediction in patients with established cardiovascular disease. By quantifying natriuretic peptides such as BNP and NT‑proBNP, clinicians can stratify patients into low, intermediate, or high risk for heart‑failure decompensation, rehospitalization, or mortality. This segment, representing approximately 30 % of market revenue, is driven by chronic disease management programs, payer incentives for preventive care, and the need for frequent, low‑cost monitoring outside laboratory settings. LFA platforms enable point‑of‑care sampling in primary‑care offices, home health visits, and remote clinics, thereby expanding the testing footprint beyond acute care. The prognostic slice also benefits from emerging algorithms that combine biomarker data with clinical variables to generate composite risk scores, increasing the clinical value proposition. Consequently, the lfa based cardiac marker segmentation for prognostic use underpins a growing share of the market as health systems shift toward value‑based care and early intervention strategies. Moreover, integration with telehealth platforms allows real‑time data transmission to cardiology specialists, facilitating timely therapeutic adjustments and reducing hospital readmission rates.
